Page 15 of 32 · 745 questions tagged clinical-trials.
I have photographs before and after reconstitution if the visual detail matters. I have worked this out and I would like someone to find the error, because I suspect…
What I am working with: SURPASS-2 · reflux · 15 mg. I would like help reading this properly rather than being told what conclusion to reach. I have the full report…
Conditions: SURMOUNT-1 · 10 mg. I would like to know the limits of what can be inferred from this. What I am trying to avoid is over-reading a single result, which I…
Numbers first: 5 mg · dulaglutide. I would rather over-plan the first cycle and simplify later. I am prepared to do the work if someone can tell me which work…
Stated plainly: retatrutide · minus 80 °C. This is asserted often enough that I assumed it was established, and then I went looking for the source. I have searched…
FLOW tested semaglutide 1.0 mg in people with type 2 diabetes and chronic kidney disease, and reported a hazard ratio of 0.76 for its composite kidney endpoint. I…
I have the full paper rather than the abstract, and the supplementary appendix. I would rather understand the derivation than memorise the outcome. Two people I asked…
The specifics, since they change the answer: SURMOUNT-2 · headache. I have the document in front of me and I can read the numbers. What I cannot do is interpret them.…
The specifics, since they change the answer: STEP 8 · nausea · 1 mg. I want to understand what this actually establishes, as opposed to what it is being used to…
I noticed that the placebo arms in this literature do not behave consistently. STEP 1 placebo loses 2.4%. STEP 3 placebo loses 5.7%. SURMOUNT-3 placebo gains 2.5%.…
For reference: SOUL · headache · 25 mg. I want to understand what this actually establishes, as opposed to what it is being used to imply. My concern is that I am…
Stated plainly: SURPASS-3 · 5 mg. I would like help reading this properly rather than being told what conclusion to reach. I have the full report including the method…
Setup, so nobody has to ask: SURMOUNT-5 · injection-site erythema. I have read the primary source rather than the summary, which has left me with more questions. I…
The case in front of me: six weeks · oral semaglutide. The claim is plausible, which is exactly why I want to check it. I am able to read a paper if someone points me…
The case in front of me: STEP 2 · reflux. I would like to know the limits of what can be inferred from this. What I am trying to avoid is over-reading a single…
The case in front of me: semaglutide · 2–8 °C. The claim is plausible, which is exactly why I want to check it. I am able to read a paper if someone points me at one.…
Concretely: SURMOUNT-OSA · reflux. I have read the primary source rather than the summary, which has left me with more questions. I understand the headline. I do not…
I have the full paper rather than the abstract, and the supplementary appendix. I want to understand what this actually establishes, as opposed to what it is being…
Setup, so nobody has to ask: SURMOUNT-OSA · a GLP-1 receptor agonist. I have read the primary source rather than the summary, which has left me with more questions. I…
The case in front of me: sixteen weeks · oral semaglutide. I want to know whether there is evidence behind this or only repetition. I have checked the obvious…
What I am working with: SOUL · injection-site erythema · 7 mg. I have read the primary source rather than the summary, which has left me with more questions. I…
Setup, so nobody has to ask: SOUL · reflux · 7 mg. I would like help reading this properly rather than being told what conclusion to reach. I have the full report…
What I am working with: PIONEER-1 · oral semaglutide. I would like help reading this properly rather than being told what conclusion to reach. I have the full report…
Setup, so nobody has to ask: SURPASS-2 · 15 mg. I would like help reading this properly rather than being told what conclusion to reach. I have the full report…